Treating anemia of chronic disease in the primary care set- ting: cardiovascular outcomes and manage- ment recommendations. Osteopath Med Prim Care 2007;1:14.Schmidt RJ, Dalton CL: Treating anemia of chronic kidney dis- ease in the primary care setting: Cardiovascular outcomes and management ...
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (Alps). Nephrol Dial Transplant. 2021;36(9):1629–1639. (Open in a new window)PubMed (Open in a new window)Web of Science ®(...
Análisis probabilístico de minimización de costes de darbepoetin alfa frente a epoetina alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica. Valoración en la práctica clínica españolaAuthor links open overlay panelA. Sanz-Granda...
The inability to afford the cost of erythropoietin for treating anemia in patients with CKD has been reported [14]. High cost of dialysis is the most common reason for nonadherence to dialysis in India [11]. It is fair to believe that a large number of patients could die because of their...
Hematologic adverse events (neutropenia, thrombocytopenia, anemia) are usually limited to the first treatment period, may require temporary dose adaptation, are rarely a cause of treatment changes, and very rarely a cause of complications. There are no data showing that the hematologic toxicity of ...
BACKGROUND: Erythropoietin is known to improve outcomes in patients with anemia from chronic renal disease. However, there is uncertainty about the optimal timing of initiation of erythropoietin treatment in predialysis patients with non-severe anemia. METHODS: We conducted a randomized controlled trial...
Anemia in the elderly. Curr Opin Hematol. 2012;19(3):133–40. Article PubMed Google Scholar Nagaraju SP, Cohn A, Akbari A, et al. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrol....
Application of myricetin in preparing preparation for inhibiting hepcidin expression Specifically, myricetin can be used for preparing a food supplement or a medicament for preventing and treating anemia of chronic inflammation (ACI), iron-... 王福俤,穆明道,伍爱民,... 被引量: 0发表: 2014年 NOVEL...
Claimed and disclosed is a new use for a previously approved drug: erythropoietin. The present invention teaches using Erythropoetin to treat anemia caused by the combined treatment of Ribavirin and a
We analyzed both efficacy and safety data, focusing on anemia, which might be worsened by the use of combined IFN/RBV, requiring modifications in transfusional schedules and iron chelation therapy.Expert opinion: The recent approval of IFN-free regimens has rapidly changed the scenario, since they...